2026-06-10

HY spreads at distress levels - 705bps, recession-associated

HY spreads at distress levels - 705bps, recession-associated

HY spreads at distress levels - 705bps, recession-associated

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) - new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) - new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) - new revenue stream

Phase 3 trial terminated early - JOHNSON A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Ri

Phase 3 trial terminated early - JOHNSON Predicting SSRI Efficacy in Veterans With PTSD

Phase 3 trial terminated early - JOHNSON Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding W

Phase 3 trial terminated early - JOHNSON An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With

Phase 3 trial terminated early - JOHNSON An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With

Phase 3 trial terminated early - JOHNSON An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis

Phase 3 trial terminated early - JOHNSON The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing El

Phase 3 trial terminated early - ELI A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese

Phase 3 trial terminated early - ELI A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Diseas

Phase 3 trial terminated early - ELI A Study of Evacetrapib in High-Risk Vascular Disease

Phase 3 trial terminated early - ELI Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lisp

Phase 3 trial terminated early - ELI An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Di

Phase 3 trial terminated early - ELI A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants

Phase 3 trial terminated early - BRISTOL Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Phase 3 trial terminated early - BRISTOL A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Ph

Phase 3 trial terminated early - BRISTOL A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus N

Phase 3 trial terminated early - BRISTOL A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS

Phase 3 trial terminated early - BRISTOL Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular

Phase 3 trial terminated early - BIOGEN A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of

Phase 3 trial terminated early - BIOGEN Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Phase 3 trial terminated early - BIOGEN A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-St

Phase 3 trial terminated early - BIOGEN 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3 trial terminated early - AMGEN Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarti

Phase 3 trial terminated early - AMGEN Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast C

Phase 3 trial terminated early - REGENERON Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Sever

Phase 3 trial terminated early - REGENERON Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Contin

Phase 3 trial terminated early - REGENERON The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts

Phase 3 trial terminated early - REGENERON REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate

Phase 3 trial terminated early - REGENERON Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Preve

Phase 3 trial terminated early - REGENERON A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Ant

Phase 3 trial terminated early - REGENERON Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Phase 3 trial terminated early - REGENERON Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antib

Phase 3 trial terminated early - Medtronic Comparison of SCS and PMR in Patients With Refractory Angina Pectoris

Phase 3 trial terminated early - Medtronic Minimally Invasive Surgical Therapy for BPH

Phase 3 trial terminated early - Medtronic INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Dis

Phase 3 trial terminated early - Medtronic PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)

Phase 3 trial terminated early - UNITEDHEALTH At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-

Phase 3 trial terminated early - VERTEX Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinom

Phase 3 trial terminated early - VERTEX Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African Amer

Phase 3 trial terminated early - VERTEX Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumat

Phase 3 trial terminated early - VERTEX A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are

Phase 3 trial terminated early - VERTEX A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fib

Phase 3 trial terminated early - VERTEX A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Thera

Phase 3 trial terminated early - VERTEX Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin

Phase 3 trial terminated early - VERTEX A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumac

Phase 3 trial terminated early - VERTEX Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of A

Phase 3 trial terminated early - AbbVie A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or

Phase 3 trial terminated early - AbbVie HCV Test and Treat Utilizing Simplified HCV Patient Education

Phase 3 trial terminated early - AbbVie Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine

Phase 3 trial terminated early - ABBOTT Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakot

Phase 3 trial terminated early - ABBOTT Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V

Phase 3 trial terminated early - ABBOTT Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Stu

Phase 3 trial terminated early - PFIZER A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic I

Phase 3 trial terminated early - PFIZER A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Phase 3 trial terminated early - PFIZER Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Phase 3 trial terminated early - PFIZER An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures

Phase 3 trial terminated early - PFIZER Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

Phase 3 trial terminated early - PFIZER A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anx

Phase 3 trial terminated early - PFIZER Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Pa

Phase 3 trial terminated early - Merck MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibi

Phase 3 trial terminated early - Merck A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINAT

Phase 3 trial terminated early - Merck MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Phase 3 trial terminated early - Merck A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Jo

Phase 3 trial terminated early - Merck Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Phase 3 trial terminated early - Merck Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Phase 3 trial terminated early - Merck A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f®

Phase 3 trial terminated early - GILEAD Botswana Tenofovir Oral HIV Prophylaxis Trial

Phase 3 trial terminated early - GILEAD Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 3 trial terminated early - GILEAD Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Phase 3 trial terminated early - GILEAD ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifunga

Phase 3 trial terminated early - GILEAD Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B

Phase 3 trial terminated early - GILEAD The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomona

Phase 3 trial terminated early - GILEAD The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertensi

Phase 3 trial terminated early - GILEAD Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

FDA approves RIFABUTIN (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves RIFABUTIN (PFIZER) - new revenue stream

FDA approves RIFABUTIN (PFIZER) - new revenue stream

Q4-2026: Beat consensus by 5.4% - EPS $2.11 vs $2.0011 estimate

Q4-2025: Missed consensus by 197.0% - EPS $-0.21 vs $-0.0707 estimate

Q2-2025: Beat consensus by 135.1% - EPS $0.19 vs $0.0808 estimate

Q3-2025: Missed consensus by 173.0% - EPS $-0.15 vs $0.2054 estimate

Missed consensus by 41.2% - EPS $19.19 vs $32.623 estimate

Q3-2024: Missed consensus by 59.9% - EPS $11.75185 vs $29.3405 estimate

Missed consensus by 15.9% - EPS $21.924 vs $26.058 estimate

Q1-2026: Beat consensus by 9.3% - EPS $0.65 vs $0.5946 estimate

Q4-2025: Beat consensus by 5.4% - EPS $0.62 vs $0.5881 estimate

Q2-2026: Beat consensus by 46.4% - EPS $0.79 vs $0.5396 estimate

Missed consensus by 245.6% - EPS $-0.15 vs $0.103 estimate

Q4-2025: Missed consensus by 103.9% - EPS $-0.01 vs $0.2553 estimate

Q2-2025: Beat consensus by 17.6% - EPS $-0.4 vs $-0.4855 estimate

Q3-2025: Beat consensus by 9.5% - EPS $-0.36 vs $-0.3978 estimate

Q4-2025: Beat consensus by 51.7% - EPS $-0.17 vs $-0.3519 estimate

Missed consensus by 25.5% - EPS $-0.1594 vs $-0.127 estimate

Missed consensus by 89.2% - EPS $-0.28946 vs $-0.153 estimate

Q2-2026: Missed consensus by 56.8% - EPS $-0.2093 vs $-0.1335 estimate

Missed consensus by 245.4% - EPS $-0.27974 vs $-0.081 estimate

Q2-2026: Beat consensus by 77.7% - EPS $-0.46 vs $-2.0604 estimate

Q3-2025: Missed consensus by 43.9% - EPS $1.99 vs $3.5451 estimate

Q1-2026: Beat consensus by 364.7% - EPS $2.62 vs $-0.9898 estimate

Q4-2025: Missed consensus by 180.2% - EPS $-0.51 vs $0.6363 estimate

Q2-2025: Missed consensus by 10.3% - EPS $0.19 vs $0.2117 estimate

Q1-2027: Beat consensus by 85.6% - EPS $0.3 vs $0.1616 estimate

Q1-2026: Missed consensus by 6.2% - EPS $0.197 vs $0.2101 estimate

Q1-2026: Missed consensus by 17.8% - EPS $70.2 vs $85.4107 estimate

Q4-2026: Missed consensus by 10.8% - EPS $0.51 vs $0.5717 estimate

Q1-2026: Missed consensus by 14.2% - EPS $0.21 vs $0.2448 estimate

Q1-2026: Missed consensus by 22.4% - EPS $0.19 vs $0.2448 estimate

Beat consensus by 14.6% - EPS $0.11 vs $0.096 estimate

Q3-2026: Beat consensus by 30.6% - EPS $0.12 vs $0.0919 estimate

Beat consensus by 34.0% - EPS $0.13 vs $0.097 estimate

Q3-2025: Beat consensus by 36.8% - EPS $0.1 vs $0.0731 estimate

Q4-2025: Beat consensus by 15.5% - EPS $0.09 vs $0.0779 estimate

Q1-2026: Beat consensus by 25.6% - EPS $0.1 vs $0.0796 estimate

Q2-2025: Beat consensus by 45.4% - EPS $0.09 vs $0.0619 estimate

Q1-2025: Beat consensus by 67.3% - EPS $-0.08 vs $-0.2448 estimate

Q2-2025: Beat consensus by 25.3% - EPS $-0.16 vs $-0.2142 estimate

Q1-2026: Beat consensus by 19.8% - EPS $-0.09 vs $-0.1122 estimate

Q2-2025: Beat consensus by 25.1% - EPS $0.71 vs $0.5676 estimate

Q4-2025: Missed consensus by 43.0% - EPS $0.19 vs $0.3333 estimate

Q1-2026: Missed consensus by 70.5% - EPS $0.07 vs $0.2374 estimate

Q3-2025: Missed consensus by 12.5% - EPS $1.03 vs $1.1767 estimate

Q1-2026: Beat consensus by 92.5% - EPS $0.2 vs $0.1039 estimate

Q4-2025: Beat consensus by 28.8% - EPS $0.3 vs $0.2329 estimate

Q2-2025: Beat consensus by 7.2% - EPS $0.36 vs $0.3357 estimate

Q3-2025: Beat consensus by 26.0% - EPS $0.42 vs $0.3334 estimate

Q2-2025: Beat consensus by 35.7% - EPS $0.3 vs $0.2211 estimate

Q1-2026: Beat consensus by 11.4% - EPS $0.15 vs $0.1346 estimate

Q2-2025: Missed consensus by 8.8% - EPS $0.57 vs $0.6253 estimate

Q4-2025: Missed consensus by 25.8% - EPS $-0.73 vs $-0.5801 estimate

Q1-2026: Beat consensus by 31.2% - EPS $-0.21 vs $-0.3053 estimate

Q3-2025: Beat consensus by 41.6% - EPS $0.43 vs $0.3036 estimate

Q1-2026: Missed consensus by 386.0% - EPS $-1.35 vs $-0.2778 estimate

Q2-2025: Missed consensus by 62.8% - EPS $0.28 vs $0.7532 estimate

Q4-2025: Missed consensus by 409.0% - EPS $-0.9 vs $-0.1768 estimate

Q3-2025: Beat consensus by 452.6% - EPS $2 vs $0.3619 estimate

Q2-2025: Missed consensus by 337.1% - EPS $-4.15 vs $-0.9494 estimate

Q4-2025: Missed consensus by 214.8% - EPS $-1.24 vs $-0.3939 estimate

Q1-2026: Missed consensus by 145.5% - EPS $-0.62 vs $-0.2525 estimate

Q3-2025: Missed consensus by 330.1% - EPS $-1.39 vs $-0.3232 estimate

Beat consensus by 56.9% - EPS $0.32 vs $0.204 estimate

Q1-2026: Missed consensus by 13.3% - EPS $0.23 vs $0.2652 estimate

Q3-2025: Beat consensus by 36.1% - EPS $0.34 vs $0.2499 estimate

Q4-2025: Missed consensus by 37.0% - EPS $0.18 vs $0.2856 estimate

Q4-2023: Beat consensus by 16.0% - EPS $-0.06 vs $-0.0714 estimate

Missed consensus by 37.3% - EPS $-0.07 vs $-0.051 estimate

Q2-2025: Missed consensus by 15.8% - EPS $0.41 vs $0.4871 estimate

Q3-2025: Beat consensus by 6.7% - EPS $0.57 vs $0.5342 estimate

Beat consensus by 217.6% - EPS $0.27 vs $-0.2295 estimate

Beat consensus by 56.5% - EPS $-0.09 vs $-0.2069 estimate

Beat consensus by 9.3% - EPS $1.21 vs $1.107 estimate

Q1-2027: Beat consensus by 22.8% - EPS $-0.26 vs $-0.3366 estimate

Q4-2026: Beat consensus by 24.8% - EPS $0.42 vs $0.3366 estimate

Beat consensus by 445.5% - EPS $0.3 vs $0.055 estimate

Q1-2026: Beat consensus by 19.4% - EPS $1.9 vs $1.5912 estimate

Q2-2026: Beat consensus by 86.0% - EPS $-0.01 vs $-0.0714 estimate

Q3-2026: Beat consensus by 8.1% - EPS $0.82 vs $0.7587 estimate

Q2-2026: Beat consensus by 15.6% - EPS $0.388 vs $0.3356 estimate

Q4-2025: Beat consensus by 7.4% - EPS $0.287 vs $0.2673 estimate

Q2-2025: Beat consensus by 32.1% - EPS $0.193 vs $0.1461 estimate

Q4-2024: Beat consensus by 23.4% - EPS $0.165 vs $0.1337 estimate

Q1-2026: Beat consensus by 15.9% - EPS $2.55 vs $2.2011 estimate

Q3-2026: Beat consensus by 12.6% - EPS $3.17 vs $2.8157 estimate

Q2-2026: Beat consensus by 9.4% - EPS $2.63 vs $2.4035 estimate

Q1-2026: Beat consensus by 15.8% - EPS $0.39 vs $0.3368 estimate

Beat consensus by 12.2% - EPS $0.34 vs $0.303 estimate

Q2-2026: Beat consensus by 12.4% - EPS $0.23 vs $0.2046 estimate

Oil +5.86% - significant rally

Gold -4.33% - significant selloff

OSINT: Valencian teachers pause strike, reject salary hike offer

Gold -2.63% - significant selloff

OSINT: US Defense Leaders Visit Guantanamo Bay aboard CH-47F Chinook

OSINT: Ukrainian FP-5 Flamingo Cruise Missile Flies 1,000 km into Russian Airspace

OSINT: US questions and bars World Cup players, staff entry despite FIFA

BTC ETF inflow of $2266M - institutional buying

ETH ETF inflow of $178M - institutional buying

BTC open interest -46.8% - OI collapse

ETH open interest -60.4% - OI collapse

SOL open interest +258.5% - OI surge

BTC ETF inflow of $2266M - institutional buying

ETH ETF inflow of $178M - institutional buying

ETH open interest +222.7% - OI surge

BTC open interest +234.6% - OI surge

SOL open interest +247.7% - OI surge

ETH open interest +230.6% - OI surge

SOL open interest +257.3% - OI surge

BTC open interest +232.0% - OI surge

ETH open interest -25.0% - OI collapse

BTC open interest +230.0% - OI surge

SOL open interest +261.8% - OI surge

DXY RSI 70.4 - overbought (crossed above 70)

VIX at 21.9 - CAUTION territory